(Total Views: 270)
Posted On: 11/19/2018 9:32:26 AM
Post# of 72446
I’m sure most are...but honestly, management doesn’t totally control all that. The key to start ups, IMO, is managing money. ESPECIALLY in biotech. You really need a savvy financial guy in a position in the business to navigate some seriously treacherous waters. Only a misinformed person would think the company would still exist without Aspire. Was it ideal? I dunno. They are in the business of making money. I’m sure they have and will.
Where I think the company made a couple mistakes, mainly mistakes in perception which is huge with a start up, is the handling of the CRO with P results. And the handling of the MFO. The fact that the MFO hasn’t been named, looks bad. Certainly does nothing to exude investor confidence. Same with the CRO issue.
It’s my opinion that those two factors hurt the sp over the last six months more than anything.
Science is solid, I don’t believe management has any nefarious intent. But those two issues have left the company vulnerable and in turn, shareholders.
That’s how I see things.
Where I think the company made a couple mistakes, mainly mistakes in perception which is huge with a start up, is the handling of the CRO with P results. And the handling of the MFO. The fact that the MFO hasn’t been named, looks bad. Certainly does nothing to exude investor confidence. Same with the CRO issue.
It’s my opinion that those two factors hurt the sp over the last six months more than anything.
Science is solid, I don’t believe management has any nefarious intent. But those two issues have left the company vulnerable and in turn, shareholders.
That’s how I see things.
(2)
(0)
